Logo image of THC

TENET HEALTHCARE CORP (THC) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:THC - US88033G4073 - Common Stock

196.74 USD
-4.58 (-2.27%)
Last: 1/16/2026, 8:04:00 PM
199.32 USD
+2.58 (+1.31%)
After Hours: 1/16/2026, 8:04:00 PM
Fundamental Rating

6

Overall THC gets a fundamental rating of 6 out of 10. We evaluated THC against 100 industry peers in the Health Care Providers & Services industry. THC scores excellent on profitability, but there are some minor concerns on its financial health. THC scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make THC a good candidate for value investing.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • THC had positive earnings in the past year.
  • THC had a positive operating cash flow in the past year.
  • Each year in the past 5 years THC has been profitable.
  • Each year in the past 5 years THC had a positive operating cash flow.
THC Yearly Net Income VS EBIT VS OCF VS FCFTHC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

1.2 Ratios

  • THC's Return On Assets of 4.60% is fine compared to the rest of the industry. THC outperforms 74.00% of its industry peers.
  • THC's Return On Equity of 33.73% is amongst the best of the industry. THC outperforms 94.00% of its industry peers.
  • THC's Return On Invested Capital of 11.65% is amongst the best of the industry. THC outperforms 85.00% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for THC is in line with the industry average of 9.19%.
  • The 3 year average ROIC (9.25%) for THC is below the current ROIC(11.65%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.6%
ROE 33.73%
ROIC 11.65%
ROA(3y)4.91%
ROA(5y)3.9%
ROE(3y)50.24%
ROE(5y)332.92%
ROIC(3y)9.25%
ROIC(5y)8.01%
THC Yearly ROA, ROE, ROICTHC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

  • THC has a Profit Margin of 6.49%. This is amongst the best in the industry. THC outperforms 85.00% of its industry peers.
  • In the last couple of years the Profit Margin of THC has grown nicely.
  • THC's Operating Margin of 17.52% is amongst the best of the industry. THC outperforms 96.00% of its industry peers.
  • THC's Operating Margin has improved in the last couple of years.
  • THC has a Gross Margin of 82.26%. This is amongst the best in the industry. THC outperforms 96.00% of its industry peers.
  • In the last couple of years the Gross Margin of THC has remained more or less at the same level.
Industry RankSector Rank
OM 17.52%
PM (TTM) 6.49%
GM 82.26%
OM growth 3Y10.99%
OM growth 5Y11.36%
PM growth 3Y48.9%
PM growth 5YN/A
GM growth 3Y-0.23%
GM growth 5Y-0.27%
THC Yearly Profit, Operating, Gross MarginsTHC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), THC is creating some value.
  • Compared to 1 year ago, THC has less shares outstanding
  • THC has less shares outstanding than it did 5 years ago.
  • THC has a better debt/assets ratio than last year.
THC Yearly Shares OutstandingTHC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
THC Yearly Total Debt VS Total AssetsTHC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

  • THC has an Altman-Z score of 1.86. This is not the best score and indicates that THC is in the grey zone with still only limited risk for bankruptcy at the moment.
  • THC has a Altman-Z score (1.86) which is comparable to the rest of the industry.
  • THC has a debt to FCF ratio of 8.78. This is a slightly negative value and a sign of low solvency as THC would need 8.78 years to pay back of all of its debts.
  • THC's Debt to FCF ratio of 8.78 is in line compared to the rest of the industry. THC outperforms 49.00% of its industry peers.
  • A Debt/Equity ratio of 3.26 is on the high side and indicates that THC has dependencies on debt financing.
  • THC has a worse Debt to Equity ratio (3.26) than 76.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.26
Debt/FCF 8.78
Altman-Z 1.86
ROIC/WACC1.33
WACC8.78%
THC Yearly LT Debt VS Equity VS FCFTHC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

  • THC has a Current Ratio of 1.71. This is a normal value and indicates that THC is financially healthy and should not expect problems in meeting its short term obligations.
  • THC has a Current ratio of 1.71. This is in the better half of the industry: THC outperforms 68.00% of its industry peers.
  • A Quick Ratio of 1.64 indicates that THC should not have too much problems paying its short term obligations.
  • THC's Quick ratio of 1.64 is fine compared to the rest of the industry. THC outperforms 66.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.71
Quick Ratio 1.64
THC Yearly Current Assets VS Current LiabilitesTHC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 39.32% over the past year.
  • THC shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 34.84% yearly.
  • Looking at the last year, THC shows a decrease in Revenue. The Revenue has decreased by -0.56% in the last year.
  • Measured over the past years, THC shows a small growth in Revenue. The Revenue has been growing by 2.26% on average per year.
EPS 1Y (TTM)39.32%
EPS 3Y16.22%
EPS 5Y34.84%
EPS Q2Q%26.28%
Revenue 1Y (TTM)-0.56%
Revenue growth 3Y1.98%
Revenue growth 5Y2.26%
Sales Q2Q%3.26%

3.2 Future

  • THC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.65% yearly.
  • Based on estimates for the next years, THC will show a small growth in Revenue. The Revenue will grow by 3.27% on average per year.
EPS Next Y36.76%
EPS Next 2Y18.31%
EPS Next 3Y15.68%
EPS Next 5Y13.65%
Revenue Next Year2.31%
Revenue Next 2Y3.35%
Revenue Next 3Y3.88%
Revenue Next 5Y3.27%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
THC Yearly Revenue VS EstimatesTHC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B 25B
THC Yearly EPS VS EstimatesTHC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20 25

9

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 12.68, the valuation of THC can be described as correct.
  • Based on the Price/Earnings ratio, THC is valued cheaper than 85.00% of the companies in the same industry.
  • THC's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.47.
  • The Price/Forward Earnings ratio is 11.81, which indicates a very decent valuation of THC.
  • THC's Price/Forward Earnings ratio is rather cheap when compared to the industry. THC is cheaper than 86.00% of the companies in the same industry.
  • THC is valuated cheaply when we compare the Price/Forward Earnings ratio to 24.26, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 12.68
Fwd PE 11.81
THC Price Earnings VS Forward Price EarningsTHC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, THC is valued cheaply inside the industry as 91.00% of the companies are valued more expensively.
  • THC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. THC is cheaper than 81.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.51
EV/EBITDA 6.23
THC Per share dataTHC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 200

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • THC has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as THC's earnings are expected to grow with 15.68% in the coming years.
PEG (NY)0.34
PEG (5Y)0.36
EPS Next 2Y18.31%
EPS Next 3Y15.68%

0

5. Dividend

5.1 Amount

  • THC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

TENET HEALTHCARE CORP

NYSE:THC (1/16/2026, 8:04:00 PM)

After market: 199.32 +2.58 (+1.31%)

196.74

-4.58 (-2.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)10-28
Earnings (Next)02-05
Inst Owners98.45%
Inst Owner Change-0.24%
Ins Owners0.73%
Ins Owner Change-1.09%
Market Cap17.29B
Revenue(TTM)20.86B
Net Income(TTM)1.35B
Analysts81.43
Price Target238.92 (21.44%)
Short Float %3.08%
Short Ratio2.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.75%
Min EPS beat(2)10.92%
Max EPS beat(2)38.59%
EPS beat(4)4
Avg EPS beat(4)25.46%
Min EPS beat(4)10.92%
Max EPS beat(4)38.59%
EPS beat(8)8
Avg EPS beat(8)41.73%
EPS beat(12)12
Avg EPS beat(12)37.25%
EPS beat(16)16
Avg EPS beat(16)44.64%
Revenue beat(2)1
Avg Revenue beat(2)0.42%
Min Revenue beat(2)-0.28%
Max Revenue beat(2)1.13%
Revenue beat(4)2
Avg Revenue beat(4)-0.36%
Min Revenue beat(4)-2.85%
Max Revenue beat(4)1.13%
Revenue beat(8)6
Avg Revenue beat(8)0.46%
Revenue beat(12)9
Avg Revenue beat(12)0.73%
Revenue beat(16)9
Avg Revenue beat(16)-0.03%
PT rev (1m)1.35%
PT rev (3m)17.61%
EPS NQ rev (1m)-0.2%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.04%
EPS NY rev (3m)2.9%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)1.71%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.66%
Valuation
Industry RankSector Rank
PE 12.68
Fwd PE 11.81
P/S 0.83
P/FCF 11.51
P/OCF 6.98
P/B 4.31
P/tB N/A
EV/EBITDA 6.23
EPS(TTM)15.52
EY7.89%
EPS(NY)16.66
Fwd EY8.47%
FCF(TTM)17.09
FCFY8.69%
OCF(TTM)28.19
OCFY14.33%
SpS237.29
BVpS45.67
TBVpS-96.62
PEG (NY)0.34
PEG (5Y)0.36
Graham Number126.29
Profitability
Industry RankSector Rank
ROA 4.6%
ROE 33.73%
ROCE 14.7%
ROIC 11.65%
ROICexc 13.23%
ROICexgc 30.88%
OM 17.52%
PM (TTM) 6.49%
GM 82.26%
FCFM 7.2%
ROA(3y)4.91%
ROA(5y)3.9%
ROE(3y)50.24%
ROE(5y)332.92%
ROIC(3y)9.25%
ROIC(5y)8.01%
ROICexc(3y)10.01%
ROICexc(5y)8.76%
ROICexgc(3y)21.74%
ROICexgc(5y)18.93%
ROCE(3y)11.67%
ROCE(5y)10.11%
ROICexgc growth 3Y12.5%
ROICexgc growth 5Y15.11%
ROICexc growth 3Y10.5%
ROICexc growth 5Y10.87%
OM growth 3Y10.99%
OM growth 5Y11.36%
PM growth 3Y48.9%
PM growth 5YN/A
GM growth 3Y-0.23%
GM growth 5Y-0.27%
F-Score5
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 3.26
Debt/FCF 8.78
Debt/EBITDA 2.93
Cap/Depr 118.3%
Cap/Sales 4.68%
Interest Coverage 4.59
Cash Conversion 55.34%
Profit Quality 110.93%
Current Ratio 1.71
Quick Ratio 1.64
Altman-Z 1.86
F-Score5
WACC8.78%
ROIC/WACC1.33
Cap/Depr(3y)96.91%
Cap/Depr(5y)86.14%
Cap/Sales(3y)4.04%
Cap/Sales(5y)3.71%
Profit Quality(3y)126.2%
Profit Quality(5y)239.34%
High Growth Momentum
Growth
EPS 1Y (TTM)39.32%
EPS 3Y16.22%
EPS 5Y34.84%
EPS Q2Q%26.28%
EPS Next Y36.76%
EPS Next 2Y18.31%
EPS Next 3Y15.68%
EPS Next 5Y13.65%
Revenue 1Y (TTM)-0.56%
Revenue growth 3Y1.98%
Revenue growth 5Y2.26%
Sales Q2Q%3.26%
Revenue Next Year2.31%
Revenue Next 2Y3.35%
Revenue Next 3Y3.88%
Revenue Next 5Y3.27%
EBIT growth 1Y14.33%
EBIT growth 3Y13.18%
EBIT growth 5Y13.88%
EBIT Next Year44.53%
EBIT Next 3Y16.02%
EBIT Next 5Y9.84%
FCF growth 1Y31.99%
FCF growth 3Y7.04%
FCF growth 5Y14.67%
OCF growth 1Y25.72%
OCF growth 3Y9.29%
OCF growth 5Y10.67%

TENET HEALTHCARE CORP / THC FAQ

What is the ChartMill fundamental rating of TENET HEALTHCARE CORP (THC) stock?

ChartMill assigns a fundamental rating of 6 / 10 to THC.


What is the valuation status for THC stock?

ChartMill assigns a valuation rating of 9 / 10 to TENET HEALTHCARE CORP (THC). This can be considered as Undervalued.


Can you provide the profitability details for TENET HEALTHCARE CORP?

TENET HEALTHCARE CORP (THC) has a profitability rating of 9 / 10.


What is the valuation of TENET HEALTHCARE CORP based on its PE and PB ratios?

The Price/Earnings (PE) ratio for TENET HEALTHCARE CORP (THC) is 12.68 and the Price/Book (PB) ratio is 4.31.


Can you provide the expected EPS growth for THC stock?

The Earnings per Share (EPS) of TENET HEALTHCARE CORP (THC) is expected to grow by 36.76% in the next year.